Inhibition of Neutrophil Chemotaxis by 4-Hydroxy cyclophosphamide

David N. Gilbert, Patricia Starr, and Nancy Eubanks
Leslie Gilbert Infectious Diseases Laboratory, Providence Medical Center, and University of Oregon Health Sciences Center, Portland, Oregon 97213

SUMMARY

4-Hydroxy cyclophosphamide, phosphoramid mustard, and nor-nitrogen mustard are compounds considered as candidates for the biologically active, alkylating metabolite of cyclophosphamide. These compounds were tested for inhibition of chemotaxis in neutrophils from normal human donors. Of those tested, only 4-hydroxy cyclophosphamide caused a significant (p < 0.01) decrease in the chemotactic index. The chemical precursor of 4-hydroxy cyclophosphamide, 4-hydroperoxycyclophosphamide, caused a barely significant (p < 0.05) decrease; 4-ketocyclophosphamide had no effect.

INTRODUCTION

Cyclophosphamide, an alkylating agent clinically used for the treatment of neoplastic diseases, is itself inactive as an alkylating agent (1, 8, 11). Of the several metabolites identified, there is debate as to which metabolite(s) is the active alkylating agent(s). To test possible active metabolites of cyclophosphamide, we used mature neutrophils because they are easily purified (3), are nondividing (2), and their chemotactic activity is measurable (7).

Previous studies with experimental animals have emphasized the effect of cyclophosphamide on immature dividing myeloid cells (6, 12). These studies did not test the functional capacity of circulating mature nondividing myeloid cells.

The studies reported below indicate that, of the cyclophosphamide metabolites tested, only 4-hydroxy cyclophosphamide and its precursor, 4-hydroperoxycyclophosphamide, inhibit neutrophil chemotaxis significantly.

MATERIALS AND METHODS

Materials

Cyclophosphamide (Cytoxan) was provided by Mead Johnson Laboratories, Evansville, Ind. The following cyclophosphamide derivatives were provided by R. Struck, Kettering-Meyer Laboratory of the Southern Research Institute, Birmingham, Ala.: 4-ketocyclophosphamide, phosphoramid mustard, nor-nitrogen mustard and 4-hydroperoxycyclophosphamide. DMSO was obtained from Sigma Chemical Co., St. Louis, Mo.

Methods

Preparation of 4-Hydroxy cyclophosphamide. Because 4-hydroxy cyclophosphamide is unstable, it was supplied as the stable precursor, 4-hydroperoxycyclophosphamide, and then deoxygenated to 4-hydroxy cyclophosphamide immediately prior to use. For each experiment, 10 mg of 4-hydroperoxycyclophosphamide were dissolved in 0.5 ml of acetone and allowed to stand for 10 min at 20°. One drop of triethyl phosphate was added and exposure to 20° continued for 5 min. Acetone was evaporated in a stream of nitrogen. Excess triethyl phosphate and resulting triethyl phosphate were removed via vacuum pump at room temperature. The resulting 4-hydroxy cyclophosphamide was dissolved in DMSO and used in the chemotaxis experiments. Thin-layer chromatography studies (R. Struck, personal communication) demonstrate that this procedure gives an essentially quantitative yield of 4-hydroxy cyclophosphamide and 4-hydroperoxycyclophosphamide.

Preparation of Neutrophil Suspension. Leukocyte suspensions yielding approximately 85% neutrophils were prepared from heparinized (10 units/ml) venous blood obtained from healthy adult donors by utilizing standard dextran sedimentation and subsequent hypotonic lysis of erythrocytes (3). For chemotaxis studies, neutrophil preparations were more highly purified by use of Hypaque-Ficoll gradients (3). This technique yielded neutrophil cell suspensions containing 98 ± 1% neutrophils without contaminating erythrocytes or platelets. Subsequently, the neutrophils were suspended in the buffers indicated below for specific experiments.

In some experiments, the neutrophil suspensions were incubated for the time period indicated with the test alkylating agent in Gey’s buffer (9). Then the cells were washed with Gey’s buffer and utilized in the test systems described.

Measure of Neutrophil Chemotaxis and Neutrophil Random Migration. Neutrophil chemotaxis was measured by the technique of Gallin et al. (7). In brief, highly purified neutrophil preparations were suspended in chilled modified Hanks’ solution at a concentration of 2.0 × 10⁷ neutrophils/ml. Neutrophil labeling with ⁵¹Cr was accomplished by the addition of 1 µCi of Na⁵¹CrO₄ in 0.9% sodium chloride solution (New England Nuclear, Boston, Mass.) per 10⁶ neutrophils.
nutrophils. The neutrophil suspension was incubated with agitation in plastic tubes at 37°C for 30 min. The neutrophil suspension was washed with modified Hank’s solution, visible cell clumps were removed, and the remaining neutrophils were suspended in Gey’s medium. The cell concentration was adjusted to 2.3 × 10⁶ neutrophils/ml.

Modified Boyden chemotactic chambers (NeuroProbe Nucleopore Corp., Pleasanton, Calif.) with a 3-μm micro-pore membrane filters (Sartorius, West Germany) were used. The chemotactic stimulus was generated by incubation of 2.0 ml of the cell donor’s serum with 1 μg of endotoxin at 37°C for 1 hr. (Escherichia coli 0127:B8, Difco Laboratories, Detroit, Mich.).

The ⁵¹Cr-labeled neutrophil suspension was added to the upper compartment, and the chemotactic stimulus, to the lower compartment. Chambers were incubated for 3 hr at 37°C in 5% carbon dioxide and 100% humidity. Subsequently, the fluid from the upper and lower chambers was aspirated. The lower filters were removed, rinsed in 0.9% NaCl solution, and placed in individual counter vials.

To account for variable ⁵¹Cr specific activity, the cpm were adjusted to 10,000 cpm/10⁶ neutrophils. A chemotactic index was calculated as follows:

\[
\text{Observed lower filter cpm} \times 10,000 \\
\text{cpm/10⁶ neutrophils}
\]

The chemotactic index was calculated as the mean of at least 3 duplicate chambers. A random migration index was calculated in the same way using chambers which omitted the chemotactic stimulus. Standard error was used for variance estimates. Student’s t test was used to compare means. Neutrophil viability was tested by trypan blue dye exclusion (14).

RESULTS

Neutrophil Chemotaxis in Presence of Cyclophosphamide and Cyclophosphamide Metabolites. Cyclophosphamide or cyclophosphamide metabolites were added in equal concentrations to both the upper and lower compartments of the chemotactic chambers. The results are shown in Table 1. With the exception of 4-hydroxycyclophosphamide and 4-hydroperoxycyclophosphamide, neither cyclophosphamide nor any of the other metabolites tested demonstrated any effect on neutrophil chemotaxis or random migration, compared with simultaneously determined control values. At 200 nmoles/ml, 4-hydroxycyclophosphamide produced a statistically significant decrease in the chemotactic index (\(p < 0.01\)) from 2394 ± 1054 (mean ± 2 S.E.) in control chambers to 313 ± 140 in test chambers. There was no influence on random migration at any concentration of 4-hydroxycyclophosphamide tested. The precursor of 4-hydroxycyclophosphamide, 4-hydroperoxycyclophosphamide, also had an inhibitory effect on chemotaxis that barely (\(p < 0.05\)) achieved statistical significance. Cell viability was not impaired by any metabolite tested, as judged by trypan blue dye exclusion.

Control experiments were conducted to ensure that the effect of 4-hydroxycyclophosphamide was not the result of inhibition by the organic solvent DMSO, used to dissolve the metabolite. DMSO, in concentration up to 1.7 volume %, had no effect on neutrophil chemotaxis.

Neutrophil Chemotaxis after Incubation in 4-Hydroxycyclophosphamide. Since it was possible that 4-hydroxycyclophosphamide altered the complement chemotactic factor rather than the neutrophils, neutrophils were incubated in Gey’s buffer containing 4-hydroxycyclophosphamide (200 nmoles/ml) for up to 2 hr at 37°C. Control cells were incubated in buffer only. Then, the cells were washed 2 times with buffer and placed in chemotactic chambers. There was a significant reduction (\(p < 0.01\)) in the chemotactic index from 1515 ± 343 (mean ± 2 S.E.) for cells incubated in buffer to 608 ± 404 for cells incubated in 4-hydroxycyclophosphamide. There was no effect on neutrophil random migration. Neutrophil viability was judged at greater than 96% by the trypan blue exclusion technique.

Because of the possibility that 4-hydroxycyclophosphamide caused the neutrophil ⁵¹Cr membrane label to release resulting in falsely low chemotactic indexes, ⁵¹Cr-labeled neutrophils were incubated in Gey’s buffer in 4-hydroxycyclophosphamide (200 nmoles/ml) or in buffer alone in a shaking water bath at 37°C for up to 5 hr. The cell suspension was sampled every hr and centrifuged at 400 x g, the cell pellet was washed twice in buffer, and the radioactivity of the cell pellet was determined. There was no loss of the neutrophil ⁵¹Cr label over the 5-hr period in either the control or 4-hydroxycyclophosphamide-exposed cells. The variability in counting between samples was low (3.0% S.E.).

DISCUSSION

The results support a direct inhibitory but sublethal effect of 4-hydroxycyclophosphamide on neutrophils, as manifest by impaired chemotaxis. Control studies exclude the possibility of an effect of the 4-hydroxycyclophosphamide on either the membrane label or the chemotactic factor. Neutrophil viability is supported by exclusion of the vital dye trypan blue, retention of the chromium isotope membrane label, and the absence of membrane leakage of the cytoplasmic enzyme, lactate dehydrogenase, into the media (unpublished observations).

Studies of the metabolism of cyclophosphamide have identified many potentially biologically active metabolites (1, 4, 5, 10, 11, 17, 18, 19). The metabolite 4-hydroxycyclophosphamide has been considered a likely candidate for the responsible cytotoxic agent (18, 19). However, a recent in vivo study in mice questions the importance of 4-hydroxycyclophosphamide (18). After administration of cyclophosphamide i.p., no detectable 4-hydroxycyclophosphamide was found in the mouse blood by thin-layer chromatography techniques (18). In contrast, high blood levels of phosphoramide mustard and nor-nitrogen mustard were found. On the basis of these results, the alkylating activity of various metabolites and available data on in vitro cytotoxicity, it was concluded that phosphoramide mustard was the most likely biologically active alkylating metabolite of cyclophosphamide produced in vivo (18). Other authors have arrived at the same conclusion (5).

Thus, it is of interest that phosphoramide mustard in high concentration had no effect on neutrophil chemotaxis. The
same was true of nor-nitrogen mustard. The reason for this discrepancy may relate to the nonreplicating nature of the mature neutrophil.

In replicating cells alkylating agents are known to combine with cellular DNA and RNA nucleosides, resulting in interference in nucleic acid and protein biosynthesis (8, 10). Even if a lack of such binding explained the resistance of nor-nitrogen mustard and phosphoramide mustard, the nature of 4-hydroxycyclophosphamide chemotaxis inhibition is unclear. An extranuclear site of alkyl ation as recently suggested by the effect of nitrogen mustard (16). Interference with NAD function and other possible mechanisms of inhibition are presently under investiga

**REFERENCES**

Inhibition of Neutrophil Chemotaxis by 4-Hydroxycyclophosphamide

David N. Gilbert, Patricia Starr and Nancy Eubanks


Updated version: Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/37/2/456

E-mail alerts: Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions: To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions: To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.